UnitedHealth Group (UNH)
(Delayed Data from NYSE)
$575.00 USD
-2.07 (-0.36%)
Updated Sep 20, 2024 04:00 PM ET
2-Buy of 5 2
B Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
UNH 575.00 -2.07(-0.36%)
Will UNH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for UNH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for UNH
UnitedHealth at 19.09X P/E: Worth the Price or Time to Take Profits?
3 Top Large Cap Stocks for a Stable Approach: ETN, DECK, UNH
UNH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Investors Heavily Search UnitedHealth Group Incorporated (UNH): Here is What You Need to Know
Should First Trust Dow 30 Equal Weight ETF (EDOW) Be on Your Investing Radar?
UnitedHealth Group (UNH) Stock Slides as Market Rises: Facts to Know Before You Trade
Other News for UNH
Dividend Champion, Contender, And Challenger Highlights: Week Of September 22
High insulin prices spur a federal lawsuit against three pharmacy benefit managers
FTC sues prescription drug middlemen, alleging they conspired over high insulin costs
UnitedHealth, Cigna, CVS PBMs targeted by FTC over inflated insulin prices
American Century Sustainable Equity Fund Q2 2024 Commentary